case_images: PMC10662308_01
case_images: Evidence blocks supporting biomarker-drug associations for all potentially targetable alterations found in the patient's tumor sample: (A) for a BRCA2 mutation and PARP inhibitors; (B) for a PIK3CA mutation and PI3K inhibitors; (C) for FLT3 amplification and tyrosine kinase inhibitors. (D) represents the measures reflected in the evidence blocks. The shading of more blocks reflects higher confidence in the evidence supporting the effect of alteration and the feasibility of targeting the biomarker.
case_images: fonc-13-1245547-g001.jpg
case_images: PMC10662308_01_fonc-13-1245547-g001.jpg
case_images: f1
case_images: Following discussion of the case at MTB ( Figure 1 ), EGFR-targeting agents were ruled out as potential treatment options due to the presence of an oncogenic KRAS mutation.
case_images: Treatment timeline.
case_images: fonc-13-1245547-g002.jpg
case_images: PMC10662308_01_fonc-13-1245547-g002.jpg
case_images: f2
case_images: After that, rechallenge of FOLFIRI + bevacizumab was administered, the patient received 8 cycles of 5th line treatment and died within a month of the last cycle ( Figure 2 ).